 |
carbon monoxide |
|---|---|
| Trade Name | Covox |
| Orphan Indication | For use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation |
| USA Market Approval | USA |
| USA Designation Date | 2008-06-24 00:00:00 |
| Sponsor | INO Therapeutics;Perryville III Corporate Park, P. O. Box 9001;Hampton, New Jersey, 08827 |
